Stay Up to Date
Featured News
FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.
Filter by:
November 6, 2025
DTRF Update: Welcoming Incoming Executive Director
Read More about DTRF Update: Welcoming Incoming Executive Director
October 16, 2025
DTRF Hosts the 2025 “Together We Will” Weekend in Chicago
Read More about DTRF Hosts the 2025 “Together We Will” Weekend in Chicago
September 4, 2025
Newsweek Article Shines a Light on Desmoid Tumors and Other Rare Diseases
Read More about Newsweek Article Shines a Light on Desmoid Tumors and Other Rare Diseases
September 1, 2025
September is Desmoid Tumor Awareness Month!
July 28, 2025
Want to make a real impact in the desmoid tumor community?
Read More about Want to make a real impact in the desmoid tumor community?
March 11, 2025
Advocate for Desmoid Tumor Research in Congress
Read More about Advocate for Desmoid Tumor Research in Congress
February 12, 2025
Recap: February Patient Education Event in Partnership with Penn Medicine
Read More about Recap: February Patient Education Event in Partnership with Penn Medicine
February 5, 2025
Note to DTRF Patient Registry Participants re: Migration to New Platform
Read More about Note to DTRF Patient Registry Participants re: Migration to New Platform
December 10, 2024
Update: OGSIVEO® (nirogacestat) Now Available in 150 mg and 100 mg Tablets
Read More about Update: OGSIVEO® (nirogacestat) Now Available in 150 mg and 100 mg Tablets
November 8, 2024
DTRF Hosts the 2024 “Together We Will” Weekend in Houston
Read More about DTRF Hosts the 2024 “Together We Will” Weekend in Houston
June 20, 2024
Updated Desmoid Tumor Treatment Guidelines, funded in part by DTRF, Published in JAMA Oncology
June 14, 2024
